Bausch Health Co. Inc. (NYSE: BHC) reported Q1 GAAP EPS of ($1.71), which does not compare to the analyst estimate of $0.97. Revenue for the quarter came in at $2.03 billion versus the consensus estimate of $2.08 billion.

"Bausch Health entered 2021 with strong momentum as our recovery from the COVID-19 pandemic continues. Our business is generating strong cash flow, many of our leading products have increased market share in key markets, and we are advancing our pipeline," said Joseph C. Papa, chairman and CEO, Bausch Health.

"We are taking action to accelerate the strategic alternatives process to expedite the spinoff of Bausch + Lomb as we remain committed to unlocking value across our two attractive businesses. We are focused on execution and growth as we position these two strong, but dissimilar businesses as attractive growth opportunities in the markets they serve," continued Mr. Papa.

GUIDANCE:

Reaffirmed 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges

For earnings history and earnings-related data on Bausch Health Co. Inc. (BHC) click here.